The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
|Videos|March 14, 2011
Dr. Siegel Discusses the New John Theurer Cancer Center
Author(s)David S. Siegel, MD, PhD
David S. Siegel, MD, PhD, chief, Multiple Myeloma at the John Theurer Cancer Center (JTCC), discusses the new JTCC stand alone cancer center.
Advertisement
David S. Siegel, MD, PhD, chief, Multiple Myeloma at the John Theurer Cancer Center (JTCC), discusses the new JTCC stand alone cancer center. Before the construction of the new building, cancer treatment services were provided as part of the Hackensack University Medical Center.
Advertisement
Related to this article
KST-6051 received FDA fast track designation for KRAS-mutant solid tumors.
David R. Gandara, MD, discusses why PD-L1 scoring in NSCLC undercounts immunotherapy benefit and where TMB and plasma proteomics fit alongside it.
Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.
The FDA approved sevabertinib in first-line HER2-mutant lung cancer, durvalumab plus tarlatamab boosted survival in ES-SCLC, and more.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
Five Under 5: Top Oncology Videos for the Week of 9/13
4
Olaparib Maintenance Yields Promising Long-Term OS Outcomes in Asian Patients With Platinum-Sensitive, Relapsed Ovarian Cancer
5